Last updated: 2026-09-05 16:35:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Madrigal Pharmaceuticals, Inc. (MDGL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $541,31, with a market capitalization of $12,54B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $393,61 to $615,00. This page covers its latest market performance, valuation, price trends and company information.
$12,54B | |
$543,35 | |
$615,00 | |
$6,60 | |
$542,61 | |
154,02K | |
349,65K | |
-- | |
$615,00 | |
$393,61 | |
-- | |
-- |
Madrigal Pharmaceuticals, Inc. (MDGL) last closed at $542,61 as of 2026-09-04 23:59:00, unchanged from the previous close of $542,61.
During the latest regular trading session, MDGL traded between $6,60 and $615,00, with a volume of 154,02K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Madrigal Pharmaceuticals, Inc. (MDGL) moved from $543,69 to $541,31, representing a decline of 0,44% ($2,38).
The stock traded between $523,29 and $552,08 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 187,76 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66,7%
MDGL is currently trading at $541,31, placing it 66,7% of the way from its 52-week low of $393,61 to its 52-week high of $615,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 915 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Madrigal Pharmaceuticals, Inc. (MDGL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.